Trial Profile
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs T cell replacement therapy (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 18 Mar 2020 Planned End Date changed from 1 Dec 2016 to 1 Dec 2024.
- 18 Mar 2020 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2023.
- 18 Mar 2020 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2022.